[90Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: Long-term results of a phase 2 clinical trial

Cancer

Volumn 115, Issue 10, 2009, Pages 2052-2062

  Iten, Fabienne ^a   Muller, Beat ^a   Schindler, Christian ^b   Rasch, Helmut ^a   Rochlitz, Christoph ^a   Oertli, Daniel ^a   Maecke, Helmut R ^a   Muller Brand, Jan ^a   Walter, Martin A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

DOTA; Iodine refractory thyroid cancer; Somatostatin; Survival; TOC

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] Y 90; RADIOPHARMACEUTICAL AGENT; THYROGLOBULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EATING HABIT; FEMALE; HUMAN; IODINE REFRACTORY THYROID CANCER; LEUKOPENIA; LONG TERM CARE; MALE; MALNUTRITION; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE REGRESSION; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; IODINE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 65649114778     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24272     Document Type: Article

References (34)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
2. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8:148-156.
3. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol. 2002;3:407-414.
4. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155-2160.
5. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:405-407. (Pubitemid 16041869)
6. Santini F, Bottici V, Elisei R, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;87:4160-4165.
7. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol. 2008;20:19-24.
8. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labeled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417-418.
9. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941-945.
10. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq Y-DOTATOC. J Nucl Med. 2002;43:610-616. (Pubitemid 34507110)
11. 90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1038-1046.
12. 90Yttrium- DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13(22 pt 1):6696-6702.
13. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
14. Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid. 2001;11:647-659. (Pubitemid 32701585)
15. Waldherr C, Schumacher T, Pless M, et al. Radiopeptide transmitted internal irradiation of noniodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun. 2001;22:673-678.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
17. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652-658.
18. Kloos RT. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:1519-1525.
19. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.
20. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990;66:321-330.
21. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on 2 protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer. 1994;74:1348-1354.
22. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer. 1991;67:564-566.
23. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
24. 3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging. 2003;30:312-315.
25. 3]octreotate. Eur J Nucl Med Mol Imaging. 2007;34:763-771.
26. 487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518.
27. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-216.
28. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242-244.
29. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-6084.
30. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol. 2004;22:4051-4058. (Pubitemid 41199651)
31. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: ''RECIST''ing a step backwards. Clin Cancer Res. 2005;11:5223-5232.
32. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2201-2204. (Pubitemid 43855005)
33. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
34. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436-16441.